Real-world pharmacovigilance data for tirzepatide: FAERS safety profile
In this medfyle
Real-world data has limitations, but is key for pharmacovigilance. New FAERS data presented at EASD 2024 confirm a safety profile for tirzepatide similar to GLP-1RA – and in line with that seen in the clinical trials – with no safety signals for pancreatitis, retinopathy, or thyroid cancer.
About this Medfyle
©2024 Medfyle. All rights reserved.
Source: The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Events Reporting System (FAERS) database Adverse Events Reporting System (FAERS) database. Carstensen B, Mørch L, Friis S, et al. Presented at EASD 2024.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
